Next Article in Journal
Mutation of Glycosylation Sites in BST-2 Leads to Its Accumulation at Intracellular CD63-Positive Vesicles without Affecting Its Antiviral Activity against Multivesicular Body-Targeted HIV-1 and Hepatitis B Virus
Next Article in Special Issue
CRISPR-Cas9 as a Powerful Tool for Efficient Creation of Oncolytic Viruses
Previous Article in Journal
The Receptor-Binding Domain in the VP1u Region of Parvovirus B19
Previous Article in Special Issue
Big Data Offers Novel Insights for Oncolytic Virus Immunotherapy
Viruses 2016, 8(3), 63; doi:10.3390/v8030063
Review

Retargeting Strategies for Oncolytic Herpes Simplex Viruses

,
,
,
,
,
*  and *
Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna 40126, Italy
* Authors to whom correspondence should be addressed.
Academic Editors: E. Antonio Chiocca and Martine L.M. Lamfers
Received: 21 October 2015 / Revised: 22 December 2015 / Accepted: 30 December 2015 / Published: 26 February 2016
(This article belongs to the Special Issue Oncolytic Viruses)
View Full-Text   |   Download PDF [909 KB, uploaded 26 February 2016]   |   Browse Figures
SciFeed

Abstract

Most of the oncolytic herpes simplex viruses (HSVs) exhibit a high safety profile achieved through attenuation. They carry defects in virulence proteins that antagonize host cell response to the virus, including innate response, apoptosis, authophagy, and depend on tumor cell proliferation. They grow robustly in cancer cells, provided that these are deficient in host cell responses, which is often the case. To overcome the attenuation limits, a strategy is to render the virus highly cancer-specific, e.g., by retargeting their tropism to cancer-specific receptors, and detargeting from natural receptors. The target we selected is HER-2, overexpressed in breast, ovarian and other cancers. Entry of wt-HSV requires the essential glycoproteins gD, gH/gL and gB. Here, we reviewed that oncolytic HSV retargeting was achieved through modifications in gD: the addition of a single-chain antibody (scFv) to HER-2 coupled with appropriate deletions to remove part of the natural receptors’ binding sites. Recently, we showed that also gH/gL can be a retargeting tool. The insertion of an scFv to HER-2 at the gH N-terminus, coupled with deletions in gD, led to a recombinant capable to use HER-2 as the sole receptor. The retargeted oncolytic HSVs can be administered systemically by means of carrier cells-forcedly-infected mesenchymal stem cells. Altogether, the retargeted oncolytic HSVs are highly cancer-specific and their replication is not dependent on intrinsic defects of the tumor cells. They might be further modified to express immunomodulatory molecules.
Keywords: oncolytic HSV; retargeting; HER-2 oncolytic HSV; retargeting; HER-2
This is an open access article distributed under the Creative Commons Attribution License (CC BY 4.0).

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
RIS
MDPI and ACS Style

Campadelli-Fiume, G.; Petrovic, B.; Leoni, V.; Gianni, T.; Avitabile, E.; Casiraghi, C.; Gatta, V. Retargeting Strategies for Oncolytic Herpes Simplex Viruses. Viruses 2016, 8, 63.

View more citation formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

For more information on the journal, click here

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert